

Publications on FAM19A4 and miR124-2 methylation analysis

Reviews:

• Steenbergen, R.D.M. et al. (2014) Clinical implications of (epi)genetic changes in HPVinduced cervical precancerous lesions. Nat. Rev. Cancer 14, 395–405.

• Luttmer, R. et al. (2016) Management of high-risk HPV-positive women for detection of cervical (pre)cancer. Expert Rev. Mol. Diagn. **16**, 961–74.

Research articles:

• De Strooper, L.M.A. et al., (2014) Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev. Res. **7**, 1251–7.

• Luttmer, R. et al. (2016) Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study). Int. J. Cancer **138**, 992–1002.

• De Strooper, L.M.A. et al. (2014) CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J. Clin. Pathol. **67**, 1067–71.

• Verhoef, V.M.J. et al. (2014) Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer. Gynecol. Oncol. **135**, 58–63.

• Hesselink, A.T. et al. (2014) Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int. J. Cancer **135**, 880–6.

• Verhoef, V.M.J. et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. **15**, 315–22.

• Wilting, S.M. et al. (2010) Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol. Cancer **9**, 167.

• Luttmer, R. et al. (2016) *FAM19A4* methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. Br. J. Cancer **115**, 579–87.

• De Strooper, L.M.A. et al. (2016) Validation of the FAM19A4/mir124-2 DNA methylation test for both lavageand brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol. Oncol. **141**, 341–7.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at **www.qiagen.com** or can be requested from QIAGEN Technical Services or your local distributor. Trademarks: QIAGEN®, Sample to Insight® (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

1105077 10/2016 © 2016 QIAGEN, all rights reserved. PROM-9759-002

Ordering www.qiagen.com/contact | Technical Support support.qiagen.com | Website www.qiagen.com

Sample to Insight